• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用NONMEM VI基于似然法处理低于定量限的数据。

Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

作者信息

Ahn Jae Eun, Karlsson Mats O, Dunne Adrian, Ludden Thomas M

机构信息

Pharmacometrics R & D, ICON Development Solutions, Ellicott City, MD, USA.

出版信息

J Pharmacokinet Pharmacodyn. 2008 Aug;35(4):401-21. doi: 10.1007/s10928-008-9094-4. Epub 2008 Aug 7.

DOI:10.1007/s10928-008-9094-4
PMID:18686017
Abstract

PURPOSE

To evaluate the likelihood-based methods for handling data below the quantification limit (BQL) using new features in NONMEM VI.

METHODS

A two-compartment pharmacokinetic model with first-order absorption was chosen for investigation. Methods evaluated were: discarding BQL observations (M1), discarding BQL observations but adjusting the likelihood for the remaining data (M2), maximizing the likelihood for the data above the limit of quantification (LOQ) and treating BQL data as censored (M3), and like M3 but conditioning on the observation being greater than zero (M4). These four methods were compared using data simulated with a proportional error model. M2, M3, and M4 were also compared using data simulated from a positively truncated normal distribution. Successful terminations and bias and precision of parameter estimates were assessed.

RESULTS

For the data simulated with a proportional error model, the overall performance was best for M3 followed by M2 and M1. M3 and M4 resulted in similar estimates in analyses without log transformation. For data simulated with the truncated normal distribution, M4 performed better than M3.

CONCLUSIONS

Analyses that maximized the likelihood of the data above the LOQ and treated BQL data as censored provided the most accurate and precise parameter estimates.

摘要

目的

利用NONMEM VI中的新功能评估基于似然性的方法处理低于定量限(BQL)的数据。

方法

选择具有一级吸收的二室药代动力学模型进行研究。评估的方法有:舍弃BQL观测值(M1),舍弃BQL观测值但调整其余数据的似然性(M2),最大化定量限(LOQ)以上数据的似然性并将BQL数据视为删失数据(M3),以及与M3类似但以观测值大于零为条件(M4)。使用比例误差模型模拟的数据对这四种方法进行比较。还使用从正截断正态分布模拟的数据对M2、M3和M4进行比较。评估成功终止情况以及参数估计的偏差和精密度。

结果

对于用比例误差模型模拟的数据,总体性能以M3最佳,其次是M2和M1。在无对数转换的分析中,M3和M4得出的估计值相似。对于用截断正态分布模拟的数据,M4的表现优于M3。

结论

最大化LOQ以上数据的似然性并将BQL数据视为删失数据的分析提供了最准确和精确的参数估计。

相似文献

1
Likelihood based approaches to handling data below the quantification limit using NONMEM VI.使用NONMEM VI基于似然法处理低于定量限的数据。
J Pharmacokinet Pharmacodyn. 2008 Aug;35(4):401-21. doi: 10.1007/s10928-008-9094-4. Epub 2008 Aug 7.
2
Handling data below the limit of quantification in mixed effect models.在混合效应模型中处理低于定量限的数据。
AAPS J. 2009 Jun;11(2):371-80. doi: 10.1208/s12248-009-9112-5. Epub 2009 May 19.
3
Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.低于定量下限数据比例对药代动力学模型参数估算的影响。
J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):423-32. doi: 10.1007/s10928-011-9201-9. Epub 2011 May 31.
4
Ways to fit a PK model with some data below the quantification limit.用一些低于定量限的数据拟合药代动力学(PK)模型的方法。
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504. doi: 10.1023/a:1012299115260.
5
Impact of censoring data below an arbitrary quantification limit on structural model misspecification.将低于任意定量限的数据进行删失对结构模型误设的影响。
J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):101-16. doi: 10.1007/s10928-007-9078-9. Epub 2007 Oct 26.
6
Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.贝叶斯方法和最大似然法在具有低于定量限数据的药代动力学模型中的评估。
Pharm Stat. 2010 Oct-Dec;9(4):313-30. doi: 10.1002/pst.400.
7
Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.使用NONMEM分析毒代动力学数据:定量限及截尾数据替代策略的影响
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):465-79. doi: 10.1023/a:1012247131190.
8
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.参数和非参数总体方法:它们在分析临床数据集和两项蒙特卡罗模拟研究中的比较性能。
Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003.
9
A reduction in between subject variability is not mandatory for selecting a new covariate.在选择新协变量时,减少个体间变异性不是强制性的。
J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):383-92. doi: 10.1007/s10928-012-9256-2. Epub 2012 Jul 6.
10
Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.给小鼠和大鼠静脉注射DA - 125或ME2303后M1、M2、M3和M4的药代动力学比较。含氟的新型阿霉素类似物。
Biopharm Drug Dispos. 1996 Jul;17(5):373-420. doi: 10.1002/(SICI)1099-081X(199607)17:5<373::AID-BDD373>3.0.CO;2-U.

引用本文的文献

1
Population Pharmacokinetic Modeling Analysis of ASC10, a Novel Antiviral Agent Targeted COVID-19, in Chinese Healthy Subjects.新型抗新冠病毒药物ASC10在中国健康受试者中的群体药代动力学建模分析
Drug Des Devel Ther. 2025 Aug 26;19:7393-7404. doi: 10.2147/DDDT.S517282. eCollection 2025.
2
Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progression.量化影响常染色体显性遗传性肾小管间质性肾病进展速率和严重程度的临床及遗传因素。
J Pharmacokinet Pharmacodyn. 2025 Jul 24;52(4):41. doi: 10.1007/s10928-025-09989-0.
3
Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model.

本文引用的文献

1
Derivation of various NONMEM estimation methods.各种NONMEM估计方法的推导。
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):575-93. doi: 10.1007/s10928-007-9060-6. Epub 2007 Jul 10.
2
Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.两室模型中低于定量限的数据遗漏或替换对参数估计的影响。
Pharm Res. 2002 Dec;19(12):1835-40. doi: 10.1023/a:1021441407898.
3
Ways to fit a PK model with some data below the quantification limit.用一些低于定量限的数据拟合药代动力学(PK)模型的方法。
慢性戊型肝炎病毒感染移植受者中利巴韦林给药方案的制定:群体药代动力学和药效学模型
J Antimicrob Chemother. 2025 Aug 1;80(8):2158-2168. doi: 10.1093/jac/dkaf183.
4
Population Pharmacokinetic Analysis of Enalapril and Enalaprilat in Newly Treated Children with Heart Failure: Implications for Safe Dosing of Enalapril (LENA Studies).依那普利和依那普利拉在新治疗的心力衰竭儿童中的群体药代动力学分析:对依那普利安全给药的启示(LENA研究)
Clin Pharmacokinet. 2025 Jul;64(7):1103-1118. doi: 10.1007/s40262-025-01520-5. Epub 2025 Jun 3.
5
Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024.全球人群药代动力学模型应用研究:2000年至2024年的文献计量分析
Front Pharmacol. 2025 May 12;16:1548023. doi: 10.3389/fphar.2025.1548023. eCollection 2025.
6
A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific Cibisatamab.一种基于模型的方法来评估抗药抗体对生物制品药物暴露的影响:以CD3 T细胞双特异性西比沙单抗为例
CPT Pharmacometrics Syst Pharmacol. 2025 Mar 19. doi: 10.1002/psp4.70019.
7
Model-informed drug development of novel ROCK2 inhibitor TDI01: population pharmacokinetic study and simulation.新型ROCK2抑制剂TDI01的模型引导药物研发:群体药代动力学研究与模拟
Front Pharmacol. 2025 Mar 4;16:1477607. doi: 10.3389/fphar.2025.1477607. eCollection 2025.
8
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling.药代动力学建模中处理低于定量下限的删失数据的实用方法。
CPT Pharmacometrics Syst Pharmacol. 2025 Jun;14(6):1042-1049. doi: 10.1002/psp4.70015. Epub 2025 Mar 11.
9
Population Pharmacokinetics of IV Lidocaine and its Metabolites in Adult Surgical Patients.静脉注射利多卡因及其代谢产物在成年外科患者中的群体药代动力学
Pharm Res. 2025 Mar;42(3):451-473. doi: 10.1007/s11095-025-03835-1. Epub 2025 Feb 28.
10
Revolutionizing Patient-Reported Outcomes Analysis for Oncology Drug Development Using Population Models.利用群体模型革新肿瘤药物研发中患者报告结局分析
Clin Cancer Res. 2025 May 1;31(9):1580-1586. doi: 10.1158/1078-0432.CCR-24-4073.
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504. doi: 10.1023/a:1012299115260.
4
Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.使用NONMEM分析毒代动力学数据:定量限及截尾数据替代策略的影响
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):465-79. doi: 10.1023/a:1012247131190.
5
An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.贝叶斯群体药代动力学/药效学模型在剂量推荐中的应用。
Stat Med. 1995;14(9-10):971-86. doi: 10.1002/sim.4780140917.